ClinicalTrials.gg
RecruitingNCT07284784Updated Oct 30, 2026

A Study of Buntanetap in Participants With PD

A Phase 2/3 interventional study of buntanetap/posiphen in Parkinson's Disease (PD) and Deep Brain Stimulation, sponsored by Annovis Bio Inc.. Recruiting at 29 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Annovis Bio Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 30, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
57th of 1,256
500 · median 36
Started
2026
with 82 others
Phase 2/3
19 of 1,649
2 open now
Primary completion
2029-09
later than 329 of 383 live
Registered
1,568th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 57th largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 83 that started in 2026, is one of 19 in phase 2/3, reaches primary completion later than 329 of the 383 other live ones, and was the 1,568th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Read the detailed description

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

03

Conditions studied

  • Parkinson's Disease (PD)
  • Deep Brain Stimulation

Browse trials for

Keywords

  • Parkinson's Disease
  • PD
  • Deep Brain Stimulation
  • DBS
  • buntanetap
  • Open-Label
  • posiphen
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose \<21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H\&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.
  3. Female participants of * must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. Intrauterine device (IUD),
    4. Intrauterine hormone-releasing system (IUS),
    5. Bilateral tubal occlusion,
    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),
    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.
  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).
  8. Good general health with no disease expected to interfere with the study.

Exclusion criteria

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).
  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
  4. A history or current evidence of long syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.
  5. Bradycardia (\<50 bpm) or tachycardia (>100 bpm) on the at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with subunit alpha 1c () levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.
  7. renal (Chronic Kidney Disease Epidemiology Collaboration [] \<50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the [ULN] and/or total > 2.0X ULN).
  8. Any clinically significant abnormal laboratory values. Participants with liver function tests ( [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.
  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.
  12. Participation in another clinical trial with an agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
  13. A learning disability or developmental delay.
  14. Participants whom the site PI deems to be otherwise ineligible.
  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.
  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic \<90mmHg and/or diastolic \<60 mmHg) and deemed medically significant by the PI.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - buntanetap

    Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

    Drug: buntanetap/posiphen

  • Experimental
    Cohort 2 - buntanetap

    Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

    Drug: buntanetap/posiphen

Interventions

  • Drugbuntanetap/posiphen

    Drug page: Buntanetap

    buntanetap capsules 30 mg by mouth daily

06

What researchers measure

Primary outcomes

  1. Safety of buntanetap

    Safety assessments of participants with PD receiving treatment with buntanetap

    Time frame: 36-months of treatment

  2. Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

    Time frame: 36-months of treatment

  3. Treatment Emergent Adverse Events (TEAE)

    TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

    Time frame: 36-months of treatment

  4. Serious Adverse Events (SAE)

    SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

    Time frame: 36-months of treatment

07

Study locations

28 of 29 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
    • Candace Cromer · Contactcandacecromer@uabmc.edu · 205-996-4034
    • Natividad Stover, M.D. · Principal investigator
  • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
    Sun City, Arizona 85351, United States
    Recruiting
  • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
    Fountain Valley, California 92708, United States
    Recruiting
    • Evan Moreno-Davis · Contactevan@pmdi.org · 714-378-5074
    • Daniel Truong, M.D. · Principal investigator
  • Cenexel Rocky Mountain Clinical Research
    Englewood, Colorado 80113, United States
    Recruiting
  • New England Institute for Clinical Research (Ki Health Partners)
    Stamford, Connecticut 06824, United States
    Recruiting
    • Valerija Misev · ContactValerija@neinh.com · 203-914-1903
    • Peter McAllister, M.D. · Principal investigator
  • First Choice Neurology - Aventura Neurologic Associates
    Aventura, Florida 33180, United States
    Recruiting
  • Arrow Clinical Trials
    Daytona Beach, Florida 32117, United States
    Recruiting
  • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
    DeLand, Florida 32720, United States
    Recruiting
  • Ezy Medical Research Co.
    Miami, Florida 33015, United States
    Not yet recruiting
  • Professional Research Center
    Miami, Florida 33172, United States
    Recruiting
  • Renstar Medical Research
    Ocala, Florida 34470, United States
    Recruiting
  • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
    Tampa, Florida 33613, United States
    Recruiting
    • Erica Botting · Contactericabotting@usf.edu · 813-974-8026
    • Robert Hauser, M.D., MBA · Principal investigator
  • Conquest Research
    Winter Park, Florida 32789, United States
    Recruiting
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
    Recruiting
    • Elizabeth Davis · Contacte.davis@cenexel.com · 404-537-1281
    • Kimball Johnson, M.D. · Principal investigator
  • Josephson Wallack Munshower Neurology, P.C.
    Indianapolis, Indiana 46256, United States
    Recruiting
    • Tammy Root · Contacttroot@jwmneuro.com · 1-317-573-6061
    • Kristi George, M.D. · Principal investigator
  • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
    Kansas City, Kansas 66160, United States
    Recruiting
    • Kelly Lyons · Contactklyons@kumc.edu · 913-588-7159
    • Rajesh Pahwa, M.D. · Principal investigator
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Mount Sinai Hospital
    New York, New York 10019, United States
    Recruiting
  • Duke Department of Neurosurgery
    Durham, North Carolina 27710, United States
    Recruiting
    • Vera George · Contactvera.george@duke.edu · 919-668-3885
    • Kyle Mitchell, M.D. · Principal investigator
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
    Recruiting
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
    Recruiting
  • Abington Neurology
    Willow Grove, Pennsylvania 19090, United States
    Recruiting
  • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
    Charleston, South Carolina 29401, United States
    Recruiting
    • Sandra Wilson · Contactwilsosan@musc.edu · 843-792-3223
    • Vanessa Hinson, M.D., PhD · Principal investigator
  • Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
    Recruiting
    • Ye Liu · Contactyliu@neuroclinic.org · 901-747-1111
    • Kendrick Henderson, M.D. · Principal investigator
  • Veracity Neuroscience LLC
    Memphis, Tennessee 38157, United States
    Recruiting
  • Central Texas Neurology
    Round Rock, Texas 78681, United States
    Recruiting
    • Koni Lopez · Contactk.lopez@ctncpa.org · 512-218-1222
    • Elizabeth Peckham, M.D. · Principal investigator
  • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
    Charlottesville, Virginia 22903, United States
    Recruiting
    • Lauren Miller · Contactfdk5dn@uvahealth.org · 434-982-6599
    • Binit Shah, M.D. · Principal investigator
  • Inland Northwest Research
    Spokane, Washington 99202, United States
    Recruiting
    • Aaron Dahl · Contactadahl@inwresearch.com · 509-960-2818
    • Jason Aldred, M.D. · Principal investigator
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Shelby Schold · Contactsschold@mcw.edu · 414-955-0698
    • Karen Blindauer, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2029, 44 months after the start.

Of 22 phase 2/3 interventional studies under Parkinson Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 16, 2025
StartActual
Jan 9, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Nov 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Ezy Medical Research Co. · Miami, United States
  • Professional Research Center · Miami, United States
Oct 30, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU · DeLand, United StatesContact •••2400→•••2400
  • Josephson Wallack Munshower Neurology, P.C. · Indianapolis, United StatesContact •••6061→•••6061
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    2 sites added
    Show 2 added (2 United States)
    • Ezy Medical Research Co. · Miami, United States
    • Professional Research Center · Miami, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU · DeLand, United StatesContact •••2400→•••2400
    • Josephson Wallack Munshower Neurology, P.C. · Indianapolis, United StatesContact •••6061→•••6061
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284784
Lead sponsor
Annovis Bio Inc.
Collaborators
Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jan 9, 2026
Primary completion
Sep 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Sarah MacCallum, BSN RN
Contact
maccallum@annovisbio.com
484-875-3192
Alexander Morin, PhD
Contact
morin@annovisbio.com
Laurie Sanders, Ph.D.
principal investigator · Duke Clinical Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buntanetap

Start the discussion